| Catalog No. | Size | Price (USD) |
| 11159-H08H-1 | 1 mg | $1,593.67 |
| 11159-H08H-100 | 100 µg | $245.86 |
| 11159-H08H-200 | 200 µg | $380.64 |
General Information
| Formulation | Lyophilized from sterile PBS, pH 7.4. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method |
| Shipping | In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise. |
| Stability & Storage | Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
| Reconstitution | To find reconstitution info, click on 'COA' at the top of the page, enter the lot number and product size for the lot-specific COA. |
| Purity | ≥ 90 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC. ≥ 95 % as determined by SEC-MALS(Routinely tested). |
| Activity | 1.Immobilized Recombinant Human CD86 / B7-2 Protein (Fc Tag)(Cat:10699-H02H) at 2 μg/ml (100 μl/well) can bind Recombinant Human CTLA-4 Protein (His Tag) (Cat:11159-H08H), the EC 50 is 2.6-8 ng/mL(Routinely tested). 2. Measured by its ability to inhibit IL-2 secretion by stimulated Jurkat human acute T cell leukemia cells. The ED 50 for this effect is 0.05-0.3μg/mL when stimulated with 1 μg/mL Recombinant Human B7‑1/CD80(Routinely tested). 3.Captured Anti-CTLA4(Research grade Ipilimumab biosimilar) on proA Chip can bind CTLA-4 (Cat.No.11159-H08H) with an affinity constant of 20.03nM as determined in a SPR assay (Biacore T200)(Routinely tested). 4.Loaded Anti-CTLA4(Research grade Ipilimumab biosimilar) on ProA Biosensor, can bind CTLA-4 Protein, Human, Recombinant, His Tag(Cat.No.11159-H08H) with an affinity constant of 5.15nM as determined in BLI assay (Sartorius Octet Red384) (Routinely tested). 5.Loaded Recombinant Human B7-1 Protein, hFc Tag (Cat. No. 10698-H02H) on ProA Biosensor, can bind Recombinant Human CTLA-4 Protein, His Tag (Cat. No. 11159-H08H) with an affinity constant of 2.66nM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested). 6.Loaded Recombinant Human CD86 Protein, hFc Tag (Cat. No. 10699-H02H) on ProA Biosensor, can bind Recombinant Human CTLA-4 Protein, His Tag (Cat. No. 11159-H08H) with an affinity constant of 5.34nM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested). 7.Immobilized Recombinant Human CD80 / B7-1 Protein (ECD, Fc Tag) (Cat: 10698-H02H) at 2 μg/mL (100 μL/well) can bind Recombinant Human CTLA4 / CD152 Protein (His Tag) (Cat: 11159-H08H), the EC 50 is 0.1-2 ng/mL (QC tested). 8.Immobilized Recombinant Human CTLA4 / CD152 Protein (His Tag) (Cat:11159-H08H) at 2 μg/mL, add increasing concentrations of CTLA-4 x OX40 Bispecific Antibody in 50% Human serum and then add Recombinant Human OX40 Protein (His & AVI Tag), Biotinylated(Cat:10481-H49H-B) at 1μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 6.4 ng/mL (Routinely tested). |
| Protein Construction | A DNA sequence encoding the human CTLA4 (NP005205.2) extracellular domain(Lys36-Phe162) was fused with the a polyhistidine tag at the C-terminus. |
| Accession# | NP_005205.2 |
| Expressed Host | HEK293 Cells |
| Species | Human |
| Predicted N Terminal | Lys 36 |
| Molecule Mass | The recombinant human CTLA4 consists of 138 amino acids and has a predicted molecular mass of 15 kDa. As a result of glycosylation, the apparent molecular mass of human CTLA4 is approximately 22-27 kDa in SDS-PAGE under reducing conditions. The molecular weight of this protein is around 37.8 kDa verified by SEC-MALS(Routinely tested). |
Synonyms: ALPS5 Protein, Human; CD Protein, Human; CD152 Protein, Human; CELIAC3 Protein, Human; CTLA-4 Protein, Human; GRD4 Protein, Human; GSE Protein, Human; IDDM12 Protein, Human
Image / Experimental Information
| Image 1 Description | Immobilized Recombinant Human CD86 / B7-2 Protein (Fc Tag)(Cat:10699-H02H) at 2 μg/ml (100 μl/well) can bind Recombinant Human CTLA-4 Protein (His Tag) (Cat:11159-H08H), the EC 50 is 2.6-8 ng/mL(Routinely tested). |
| Image 1 Alt Text | Human CTLA-4 Protein 24439 |
| Image 1 URL | Source image |
| Image 2 Description | Immobilized Recombinant Human CD86 / B7-2 Protein (Fc Tag)(Cat:10699-H02H) at 2 μg/ml (100 μl/well) can bind Recombinant Human CTLA-4 Protein (His Tag) (Cat:11159-H08H), the EC 50 is 2.6-8 ng/mL(Routinely tested). |
| Image 2 Alt Text | Human CTLA-4 Protein 30001 |
| Image 2 URL | Source image |
| Image 3 Description | Immobilized Recombinant Human CD86 / B7-2 Protein (Fc Tag)(Cat:10699-H02H) at 2 μg/ml (100 μl/well) can bind Recombinant Human CTLA-4 Protein (His Tag) (Cat:11159-H08H), the EC 50 is 2.6-8 ng/mL(Routinely tested). |
| Image 3 Alt Text | Human CTLA-4 Protein 31763 |
| Image 3 URL | Source image |
| Image 4 Description | Immobilized Recombinant Human CD86 / B7-2 Protein (Fc Tag)(Cat:10699-H02H) at 2 μg/ml (100 μl/well) can bind Recombinant Human CTLA-4 Protein (His Tag) (Cat:11159-H08H), the EC 50 is 2.6-8 ng/mL(Routinely tested). |
| Image 4 Alt Text | Human CTLA-4 Protein 36054 |
| Image 4 URL | Source image |
| Image 5 Description | Immobilized Recombinant Human CD86 / B7-2 Protein (Fc Tag)(Cat:10699-H02H) at 2 μg/ml (100 μl/well) can bind Recombinant Human CTLA-4 Protein (His Tag) (Cat:11159-H08H), the EC 50 is 2.6-8 ng/mL(Routinely tested). |
| Image 5 Alt Text | Human CTLA-4 Protein 36067 |
| Image 5 URL | Source image |
Background Information
| Full Name | cytotoxic T-lymphocyte-associated protein 4 |
| Description | Cytotoxic T-lymphocyte protein 4, also known as CTLA4 and CD152, is a single-pass type I membrane protein and a member of the immunoglobulin superfamily. It is the second member of the CD28 receptor family. The ligands or counterreceptors for these two proteins are the B7 family members, CD80 (B7-1) and CD86 (B7-2). CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may play an important role in their functions. CD152 or cytotoxic T lymphocyte antigen-4 (CTLA-4) is an essential receptor involved in the negative regulation of T cell activation. Because of its profound inhibitory role, CD152 has been considered a sound susceptible candidate in autoimmunity and a persuasive target for cancer immunotherapy. In particular, recent evidence suggests that CD152 is also important in the homeostasis and function of a population of suppressive cells, termed regulatory T cells (Treg). |
| Research Areas |
|
| Tags |
|
| References |
|
title: Conjugates of biomolecule and use thereof
authors: Yuan Liu; Haiyang Wang; ...; Cheng Liu
date: 2026-03-03
cited_by_count: 0
techniques: Conjugation Assay; Enzyme-linked Immunosorbent Assay; Mutagenesis
bioz_score: 95
title: Self-assembly of hybrid 3D cultures by integrating living and synthetic cells
authors: Nils Piernitzki; Ning Gao; ...; Oskar Staufer
journal: Nature Communications
date: 2025-12-10
pmid: 41372132
doi: 10.1038/s41467-025-66789-3
cited_by_count: 6
techniques: Sequencing
bioz_score: 94
title: CD80 variant proteins and uses thereof
authors: Yuntao Song; Jianhui Zhou; ...; Chen Dong
date: 2025-08-05
cited_by_count: 0
techniques: Binding Assay; Enzyme-linked Immunosorbent Assay; Injection; Mutagenesis; Software
bioz_score: 93
title: Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
authors: Myung Ho Jang
date: 2025-05-06
cited_by_count: 0
techniques: Activation Assay; Binding Assay; Concentration Assay
bioz_score: 93
title: Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
authors: Dhan Chand; David A. Savitsky; ...; Robert B. Stein
journal: Cancer Discovery
date: 2024-12-02
pmid: 39083809
doi: 10.1158/2159-8290.CD-24-0190
pmcid: 11609826
cited_by_count: 18
techniques: Recombinant
bioz_score: 93
title: A Novel Monoclonal Antibody against PD-1 for the Treatment of Viral Oncogene-Induced Tumors or Other Cancer
authors: Xu Xu; Shih-Long Yan; ...; Yosef Sabo
journal: Cancers
date: 2024-09-01
doi: 10.3390/cancers16173052
pmcid: 11393876
cited_by_count: 1
techniques: Activation Assay; Binding Assay; Competitive ELISA; Concentration Assay; Enzyme-linked Immunosorbent Assay; High Performance Liquid Chromatography; In Vitro; Incubation; Negative Control; Positive Control
bioz_score: 93
title: A study on the efficacy and Safety Evaluation of a novel PD-1/CTLA-4 bispecific antibody.
authors: Qi Song; Meiling Jiang; ...; Xiaomeng Zhang
journal: Immunobiology
date: 2024-08-30
pmid: 39226691
doi: 10.1016/j.imbio.2024.152844
cited_by_count: 0
techniques: SPR Assay; Software
bioz_score: 95
title: Developing a platform for secretion of biomolecules in Mycoplasma feriruminatoris
authors: Javier Gonzalez-de-Miguel; Ariadna Montero-Blay; ...; Luis Serrano
journal: Microbial Cell Factories
date: 2024-04-30
doi: 10.1186/s12934-024-02392-3
pmcid: 11059754
cited_by_count: 0
techniques: Activation Assay; Binding Assay; Enzyme-linked Immunosorbent Assay; Gentle; Incubation; Membrane; Produced; Recombinant
bioz_score: 95
title: Pharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug
authors: Myung Ho Jang; Su Youn Nam; Young Jun Koh
date: 2024-01-02
cited_by_count: 0
techniques: Activation Assay; Binding Assay; Concentration Assay
bioz_score: 93
title: HOW I DIAGNOSE AND TREAT ANTIPHOSPHOLIPID SYNDROME IN PREGNANCY.
authors: D Ware Branch; Ming Y Lim
journal: Blood
date: 2023-12-25
pmid: 38145574
doi: 10.1182/blood.2023020727
cited_by_count: 10
techniques: Activity Assay; Binding Assay; Blocking Assay; Enzyme-linked Immunosorbent Assay; Incubation; Inhibition; Negative Control; Recombinant; Spectrophotometry
bioz_score: 93
title: CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment
authors: Musleh M Muthana; Xuexiang Du; ...; Betty Diamond
journal: eLife
date: 2023-12-21
pmid: 38127423
doi: 10.7554/eLife.87281
pmcid: 10735222
cited_by_count: 7
techniques: Activation Assay; Binding Assay; Blocking Assay; Conjugation Assay; Enzyme-linked Immunosorbent Assay; Expressing; Extraction; Flow Cytometry; Fluorescence; Incubation; Knock-In; Mutagenesis; Neutralization; SDS-Gel; Serial Dilution; Two Tailed Test
bioz_score: 94
title: Antitumor effect of plant-produced anti-CTLA-4 monoclonal antibody in a murine model of colon cancer
authors: Christine Joy I. Bulaon; Narach Khorattanakulchai; ...; Waranyoo Phoolcharoen
journal: Frontiers in Plant Science
date: 2023-08-29
doi: 10.3389/fpls.2023.1149455
pmcid: 10497774
cited_by_count: 4
techniques: Activity Assay; Binding Assay; Concentration Assay; Derivative Assay; Enzyme-linked Immunosorbent Assay; Expressing; Generated; In Vivo; Incubation; Membrane; Molecular Weight; Produced; Purification; Recombinant; SDS Page; Size-exclusion Chromatography; Staining; Virus; Western Blot
bioz_score: 93
title: CTLA4 protects against maladaptive cytotoxicity during the differentiation of effector and follicular CD4 + T cells.
authors: Yuwei Hao; Bahar Miraghazadeh; ...; Matthew C Cook
journal: Cellular & molecular immunology
date: 2023-07-04
pmid: 37161048
cited_by_count: 6
techniques: Blocking Assay; Comparison; Cytometry; Expressing; Flow Cytometry; Incubation; Infection; Injection; Irradiation; Mutagenesis; Plasmid Preparation; Positive Control; Purification; Sequencing; Staining; Transfection; Two Tailed Test
bioz_score: 95
title: Pharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an IL-2 mutant and a CD80 extracellular domain
authors: Myoung Ho Jang; Su Youn Nam; ...; Young-Gyu Cho
date: 2023-05-02
cited_by_count: 0
techniques: Activation Assay; Binding Assay; Concentration Assay
bioz_score: 94
title: FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodies
authors: Knorr David; Leidner Rom; ...; Ravetch Jeffrey
journal: bioRxiv
date: 2023-01-20
cited_by_count: 0
techniques: Activity Assay; Binding Assay; Blocking Assay; Enzyme-linked Immunosorbent Assay; Expressing; Flow Cytometry; Fluorescence; Generated; In Vivo; Incubation; Inhibition; Labeling; Negative Control; Recombinant; SPR Assay; Sequencing; Spectrophotometry; Variant Assay
bioz_score: 94
title: Anti-CTLA-4 antibodies and methods of use thereof
authors: Marc Van Dijk; Cornelia Anne Mundt; ...; Nicholas Stuart Wilson
date: 2022-03-08
cited_by_count: 0
techniques: Recombinant; SPR Assay
bioz_score: 94
title: Multi-specific polypeptide useful for localized tumor immunomodulation
authors: Shane Olwill; Alexander Wiedenmann; ...; Bradley Lunde
date: 2021-02-23
cited_by_count: 0
techniques: Binding Assay; Incubation; Positive Control; SPR Assay
bioz_score: 93
title: Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
authors: Serengulam V. Govindan; David M. Goldenberg
date: 2021-02-16
cited_by_count: 0
techniques: Migration
bioz_score: 94
title: Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer
authors: Darren J. Schofield; Jennifer Percival-Alwyn; ...; Michael Oberst
journal: mAbs
date: 2021-01-04
pmid: 33397194
doi: 10.1080/19420862.2020.1857100
pmcid: 7831362
cited_by_count: 18
techniques: Activity Assay; Binding Assay; Enzyme-linked Immunosorbent Assay; Fluorescence; In Vivo; Inhibition; Mutagenesis; Recombinant; SPR Assay; Standard Deviation
bioz_score: 93
title: Deep Mining of Complex Antibody Phage Pools Generated by Cell Panning Enables Discovery of Rare Antibodies Binding New Targets and Epitopes
authors: Anne Ljungars; Carolin Svensson; ...; Mikael Mattsson
journal: Frontiers in Pharmacology
date: 2019-07-30
pmid: 31417405
doi: 10.3389/fphar.2019.00847
pmcid: 6683657
cited_by_count: 28
techniques: Blocking Assay; Construct; Expressing; Incubation; Microarray
bioz_score: 93
title: Generation of orthogonal Fab-based trispecific antibody formats.
authors: Xiufeng Wu; Richard Yuan; ...; Stephen J Demarest
journal: Protein engineering, design & selection : PEDS
date: 2019-02-18
pmid: 29718394
doi: 10.1093/protein/gzy007
cited_by_count: 8
techniques: Binding Assay; Produced; SPR Assay; Software
bioz_score: 93
title: Antibody-drug conjugates and uses thereof
authors: David M. Goldenberg; Serengulam V. Govindan
date: 2018-11-20
cited_by_count: 0
techniques: Migration
bioz_score: 94
title: Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens
authors: Jeremy D. Waight; Dhan Chand; ...; Nicholas S. Wilson
journal: Cancer cell
date: 2018-06-11
pmid: 29894690
doi: 10.1016/j.ccell.2018.05.005
pmcid: 6292441
cited_by_count: 86
techniques: Expressing; Flow Cytometry; Generated; Recombinant; Software; Staining
bioz_score: 93
title: Stability-Diversity Tradeoffs Impose Fundamental Constraints on Selection of Synthetic Human V H /V L Single-Domain Antibodies from In Vitro Display Libraries
authors: Kevin A. Henry; Dae Young Kim; ...; Jamshid Tanha
journal: Frontiers in Immunology
date: 2017-12-12
pmid: 29375542
doi: 10.3389/fimmu.2017.01759
pmcid: 5763143
cited_by_count: 14
techniques: Binding Assay; Enzyme-linked Immunosorbent Assay; Isolation; Recombinant
bioz_score: 93
